News

Higher Tyvaso Doses Better at Preventing PH-ILD Worsening

A high dose of Tyvaso (inhaled treprostinil) — at least nine breaths four times per day — is more effective at preventing clinical worsening than lower doses for people with pulmonary hypertension associated with interstitial lung disease (PH-ILD), a new study indicates. “This analysis further reinforces that [Tyvaso]…

Study: Ang-2 Blood Test May Predict Treatment Outcomes in CTEPH

A blood test for angiopoietin-2 (Ang-2), a protein associated with forming new blood vessels, may predict treatment outcomes in people with chronic thromboembolic pulmonary hypertension (CTEPH), a study showed. Researchers found that the protein’s level was significantly higher in the bloodstream of patients with this rare form of…

Aqualung Awarded $4.8M From NIH to Develop Monoclonal Antibody

The National Institutes of Health (NIH) has granted Aqualung Therapeutics two three-year awards totaling $4.8 million to develop ALT-100, a humanized monoclonal antibody, for the treatment of pulmonary arterial hypertension (PAH) and inflammatory bowel disease (IBD). ALT-100 is designed to address and prevent inflammation in severe inflammatory…

High WIF-1 Blood Levels May Suggest Poorer PH-LHD Outcomes

Levels of the Wnt inhibitory factor 1 (WIF-1) protein were elevated in the blood of people with pulmonary hypertension (PH) associated with left-sided heart failure, according to a new study. WIF-1 was linked with higher levels of NT-proBNP — a marker of heart failure — as well as several…

Pulnovo’s PADN Device Yields Improved Outcomes in PAH Trial

Treatment with Pulnovo Medical‘s pulmonary artery denervation (PADN) device improved exercise capacity, blood flow dynamics, and clinical outcomes for pulmonary arterial hypertension (PAH) patients in a clinical trial called PADN-CFDA, the company announced. “The PADN-CFDA results are very important because this was an adequately powered randomized controlled trial,…

Grant Helps Eko Develop AI Algorithm for Detecting PH

Digital health company Eko has been awarded $2.7 million from the National Institutes of Health (NIH) to develop an artificial intelligence (AI)-based algorithm that can detect pulmonary hypertension (PH) and classify its severity. The algorithm will analyze data from two common, noninvasive heart tests collected via Eko’s digital smart…